biotech · Multiple Myeloma · Multiple Myeloma (MM) · CCCC
C4 Therapeutics
C4 Therapeutics is a biotech organization headquartered in WATERTOWN, MA, USA. It trades on NYSE under ticker CCCC. Primary therapeutic focus areas include Multiple Myeloma, Multiple Myeloma (MM), Solid Tumors, Synovial
WATERTOWN, MA, USA HQ
2024 Founded
2 Employees
Public company Type
CCCC · NYSE Ticker
Company details
- Status
- Public
- HQ
- WATERTOWN, MA, USA
- Founded
- 2024
- Employees
- 2
- Programs
- 4
- Drugs
- 1
- Patents
- 24
cemsidomide
Phase 2 · small molecule · Multiple Myeloma
cemsidomide for Multiple Myeloma is a Phase 2 program (small_molecule) at C4 Therapeutics with 2 ClinicalTrials.gov record(s).
Internal code CFT7455-1101
Full intelligence profile for this program is being prepared.
At a glance
- Sponsor
- C4 Therapeutics
- Phase
- Phase 2
- Modality
- small_molecule
- Indication
- Multiple Myeloma
- Status
- active
- Trials
- 2